New combo therapy aims to tackle tough prostate cancer
NCT ID NCT07172685
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a combination of hormone therapy, chemotherapy, and targeted ultrasound for men with metastatic prostate cancer that has spread widely. The goal is to see if adding focused ultrasound to standard triple therapy can better control the disease. About 116 men will take part in this single-arm trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Darolutamide, Docetaxel, ADT (hormone therapy), and High-Intensity Focused Ultrasound (HIFU)
What this could lead to
If successful, this combination could improve control of metastatic prostate cancer and delay disease progression.
What could go wrong
This is an early exploratory study with only 116 participants, so results may not apply to all patients. The added HIFU procedure carries risks like infection or urinary issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qilu hospital
RECRUITINGJinan, Shandong, 276600, China
Contact Phone: •••-•••-•••• Email: •••••@•••••